Single-cell analysis identifies CPT1a-associated metabolic remodeling in human NK cells during COVID-19
The Journal of Immunology · 2026
DOI: 10.1093/jimmun/vkag036 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2026. Verfasst von Sarah Benezech und 10 weiteren Autor:innen. Beteiligte Einrichtung: UMR5308, INSERM U1111, Centre International de Recherche en Infectiologie, Centre National de la Recherche Scientifique, Université de Lyon, Universi…. Hauptthemen laut MEDLINE: Killer Cells, Natural, Carnitine O-Palmitoyltransferase, COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: INSERM, Centre National de la Recherche Scientifique, Université Claude Bernard Lyon 1 and École Normale Supérieure de Lyon.
Abstract (Originalsprache)
Natural killer (NK) cells are critical for early antiviral immunity, yet their metabolic regulation during acute human viral infection remains incompletely understood. We analyzed NK cell activation and metabolic reprogramming in 47 vaccinated individuals with mild breakthrough SARS-CoV-2 infection and 20 matched healthy control subjects. COVID-19 patients exhibited elevated plasma interferon α and NK cell activation markers (CD69, CD38), alongside increased basal STAT5 phosphorylation, consistent with IL-15–mediated signaling. Functionally, NK cells from infected subjects displayed heightened cytotoxicity. Metabolic profiling at the single-cell level revealed increased cell size, translational activity, amino acid and glucose uptake, and mitochondrial membrane potential, indicating a globally activated metabolic state specific to NK cells. Using newly developed spectral cytometry panels targeting metabolic regulators, we identified CPT1a as the most discriminative marker between patient and control NK cells, with elevated expression in both CD56bright and CD56dim subsets. CPT1a levels correlated with CD38 expression and with uptake of the fluorescent palmitate analog BODIPY-FL C16, reflecting enhanced long-chain fatty acid oxidation. These changes were absent in B and T lymphocytes. Our findings support that during SARS-CoV-2 infection, human NK cells undergo coordinated cytokine-driven activation and metabolic remodeling, integrating glycolysis and lipid oxidation to support amplified effector function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UMR5308, INSERM U1111, Centre International de Recherche en Infectiologie, Centre National de la Recherche Scientifique, Université de Lyon, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, Lyon, Fran…
- Hospices Civils de Lyon, Lyon, France.
- Laboratoire de Virologie, Institut des Agents Infectieux, Centre National de Référence des Virus des Infections Respiratoires, Hospices Civils de Lyon, Lyon, France.
ORCID-Profile: Alexandre Belot
Förderung
- INSERM
- Centre National de la Recherche Scientifique
- Université Claude Bernard Lyon 1 and École Normale Supérieure de Lyon
- ANRS grants
Zitieren
APA
Benezech, S., Picq, L., Villard, M., Rousseaux, N., Hamond, A., Allatif, O., Bal, A., Belot, A., Trouillet-Assant, S., Marçais, A., & Walzer, T. (2026). Single-cell analysis identifies CPT1a-associated metabolic remodeling in human NK cells during COVID-19. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkag036
Vancouver
Benezech S, Picq L, Villard M, Rousseaux N, Hamond A, Allatif O, et al. Single-cell analysis identifies CPT1a-associated metabolic remodeling in human NK cells during COVID-19. The Journal of Immunology. 2026. doi:10.1093/jimmun/vkag036
BibTeX
@article{Benezech2026,
author = {Benezech, Sarah and Picq, Louis and Villard, Marine and Rousseaux, Noémi and Hamond, Ameline and Allatif, Omran and Bal, Antonin and Belot, Alexandre and Trouillet-Assant, Sophie and Marçais, Antoine and Walzer, Thierry},
title = {Single-cell analysis identifies CPT1a-associated metabolic remodeling in human NK cells during COVID-19},
journal = {The Journal of Immunology},
year = {2026},
doi = {10.1093/jimmun/vkag036}
}
EUVIMED